Evidence map›Paper›PMID 40380326›Full record

ArticleJournal of nanobiotechnology2025

A spreadable self-gelling hemostatic powder sensitizes CAR-NK cell therapy to prevent hepatocellular carcinoma recurrence postresection.

Yusheng Cheng, Yihang Gong, Xin Li, Fanxin Zeng, Bo Liu, Wenjie Chen, Feng Zhang, Haofei Chen, Weixiong Zhu, Hui Li and 3 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of nanobiotechnology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Review
  3. Article
  4. Review
  5. Review
  6. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Yusheng Cheng *The Second Clinical Medical School of Lanzhou University, Lanzhou, 730000, China.
Yihang Gong *Department of Hepatic Surgery and Liver Transplantation Center, Organ Transplantation Institute, Organ Transplantation Research Center of Guangdong Province, Guangdong Province Engineering Laboratory for Transplantation Medicine, The Third Affiliated Hospital of Sun Yat-sen University, Sun Yat-sen University, Guangzhou, 510630, China.
Xin Li *The Second Clinical Medical School of Lanzhou University, Lanzhou, 730000, China.
Fanxin Zeng *Department of Hepatic Surgery and Liver Transplantation Center, Organ Transplantation Institute, Organ Transplantation Research Center of Guangdong Province, Guangdong Province Engineering Laboratory for Transplantation Medicine, The Third Affiliated Hospital of Sun Yat-sen University, Sun Yat-sen University, Guangzhou, 510630, China.
Bo Liu *The Second Clinical Medical School of Lanzhou University, Lanzhou, 730000, China.
Wenjie ChenBiotherapy Centre & Cell-gene Therapy Translational Medicine Research Centre, The Third Affiliated Hospital, Sun Yat-sen University, Guangzhou, 510630, China.
Feng ZhangBiotherapy Centre & Cell-gene Therapy Translational Medicine Research Centre, The Third Affiliated Hospital, Sun Yat-sen University, Guangzhou, 510630, China.
Haofei ChenGansu Province Precision Diagnosis and Treatment Engineering Research Center of Hepatobiliary Pancreatic Diseases, Gansu Province Key Laboratory of Environmental Oncology, Lanzhou, 730000, China.
Weixiong ZhuThe Second Clinical Medical School of Lanzhou University, Lanzhou, 730000, China.
Hui LiDepartment of Hepatobiliary Pancreatic Tumor Center, Chongqing Key Laboratory of Translational Research for Cancer Metastasis and Individualized Treatment, Chongqing University Cancer Hospital, Chongqing, 400030, China. lih@cqu.edu.cn.
Lei ZhouGuangzhou Key Laboratory of Spine Disease Prevention and Treatment, Department of Orthopaedic Surgery, The Third Affiliated Hospital of Guangzhou Medical University, Guangzhou, 510150, China. zhoul@gzhmu.edu.cn.
Tiangen WuDepartment of Hepatobiliary & Pancreatic Surgery, Zhongnan Hospital of Wuhan University, Wuhan, Hubei, 430071, PR China. wtg666@whu.edu.cn.
Wence ZhouThe Second Clinical Medical School of Lanzhou University, Lanzhou, 730000, China. zhouwc129@163.com.

Funding

National Natural Science Foundation of China 82260555National Natural Science Foundation of China 82303474National Natural Science Foundation of China 82360550
6 · The paper itself

Abstract

Adoptive natural killer cell therapy (ANKCT) harbors great potential for combating postsurgical hepatocellular carcinoma (HCC) recurrence, but its efficacy is limited by tumor microenvironment (TME)-meditated repression on NK cell function and insufficient NK cell homing to tumor sites. Therefore, herein we develop a nanocomposite sprayable self-gelling powder enabling liver-localized codelivery of three FDA-approved drugs including calcitriol (Cal), gemcitabine (Gem), and tazemetostat (Taz) to address these challenges. This powder can be laparoscopically spread to liver wound sites, where it rapidly absorbs interfacial liquid to form a bulk adhesive pressure-resistant hydrogel in situ, implying its application potential in minimally surgery. Moreover, its application to liver resection bed significantly sensitizes allogenic NK and EpCAM chimeric antigen receptor modified-NK-92 (EpCAM-CAR-NK) cell infusion to prevent HCC recurrence in orthotopic Heap1-6 tumor-bearing and patient-derived tumor xenograft (PDX) HCC murine models. Additionally, this powder can allow for an effective hemostatic effect in rat and porcine models due to its powerful tissue adhesion-seal and erythrocyte-aggregating effects. Altogether, our newly developed hemostatic self-gelling powder can significantly sensitize ANKCT to combat HCC recurrence in a manner compatible with surgical treatment of HCC.

Indexed as

Carcinoma, HepatocellularHemostaticsImmunotherapy, AdoptiveKiller Cells, NaturalLiver NeoplasmsNeoplasm Recurrence, LocalAnimalsCell Line, TumorHumansMaleMicePowdersRatsReceptors, Chimeric AntigenSwineHemostaticsPowdersReceptors, Chimeric AntigenDrug deliveryHemostasisHepatocellular carcinomaNanocomposite hydrogelNK cell therapy

Identifiers

PMID40380326
PMCPMC12082949

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.